Application of 1, 3, 5-tri (4-boric acid phenyl) benzene in preparation of pyroptosis inducer

By using 1,3,5-tris(4-borate phenyl)benzene as a pyroptosis inducer, the problems of limited types and high cost in the prior art are solved, and low-cost and efficient pyroptosis induction are achieved. , overcome side effects and biotoxicity, and broaden its application in tumor treatment and other fields.

CN119074741AActive Publication Date: 2024-12-06ZHEJIANG UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411226552.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-12-06
Estimated Expiration
2044-09-03

AI Technical Summary

Technical Problem

The existing reagents used to induce pyroptosis are limited in types and costly, which limits their application in clinical treatment and research.

Method used

1,3,5-tris(4-borate phenyl)benzene is used as a pyroptosis inducer, and pyroptosis is induced through its structural design, and can be combined with other active ingredients to reduce costs and broaden the scope of application.

Benefits of technology

1,3,5-tris(4-borate phenyl)benzene can effectively induce pyrolysis, with a low cost, and overcomes the side effects of existing pyrolysis inducers and biological Toxicity provides a new low-cost and efficient induction of pyroptosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074741A_ABST
    Figure CN119074741A_ABST
Patent Text Reader

Abstract

The invention relates to the field of medicinal chemistry, discloses an application of 1, 3, 5-tri (4-boric acid phenyl) benzene in preparation of a pyroptosis inducer, and finds that the 1, 3, 5-tri (4-boric acid phenyl) benzene has the characteristic of inducing pyroptosis for the first time, is simple to prepare and relatively low in cost, and is expected to be industrially produced and utilized on a large scale. In addition, the boric acid group has great modification potential, can be widely applied to drug development, and has popularization and application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to application of 1,3,5-tris(4-boronic acid phenyl)benzene in the preparation of a cell pyroptosis inducer. Background Art

[0002] With the continuous development of the medical field, the diversity and complexity of programmed cell death have been extensively studied. Pyroptosis, as a recently discovered form of programmed cell death, has attracted widespread attention for its unique cell death process and its role in the innate immune response. Pyroptosis is characterized by a significant expansion of the cell volume, and eventually the cell membrane ruptures and the release of the contents.

[0003] Since 2015, Academician Shao Feng and his team have made breakthrough progress in the field of cell pyroptosis. Studies have found that caspase-1 and caspase-11 / 4 / 5 trigger cell pyroptosis by cleaving Gasdermin-D (GSDMD) protein (Shi et al., Nature 2015; Ding et al., Nature 2016). After the GSDMD protein is cleaved by the corresponding caspase, its N-terminal domain is released and can bind to cell membrane lipids to form holes in the cell membrane. This process causes changes in intracellular osmotic pressure, which in turn causes the cell to continue to swell until the cell membrane ruptures.

[0004] Cell pyroptosis plays an important role in the body's natural immune response, especially in fighting infection and responding to endogenous danger signals. In the field of tumor treatment, effective induction of tumor cell pyroptosis can not only eliminate tumor cells, but also activate local autoimmune responses through the released contents, thus providing a new strategy for tumor immunotherapy. However, the types of reagents that can be used to induce cell pyroptosis are limited and the cost is high, which greatly limits its application and development in clinical treatment.

[0005] In order to overcome the above problems, researchers are committed to developing new compounds or drugs that can induce cell pyroptosis. In this context, Chinese patent CN116730976A discloses the preparation and application of a class of light-controlled pyroptosis inducers (PyPSs) targeting the endoplasmic reticulum of cells. A method for a new light-controlled material to induce GSDME-mediated pyroptosis is demonstrated. Through the endoplasmic reticulum-targeted pyroptosis inducer, a variety of cancer cells are caused to produce ROS under light conditions, and then caspase-3 is activated. The activated caspase-3 can cleave GSDME to form the N-terminal fragment of GSDME (GSDME-N). GSDME-N causes cell membrane perforation, cell swelling and release of inflammatory components, ultimately leading to cell pyroptosis. This type of pyroptosis inducer can cause pyroptosis of a variety of cancer cells under both normoxic and hypoxic conditions, and has broad application prospects in the field of tumor treatment.

[0006] In addition, patent CN 112939951A discloses a pyroptosis drug prodrug, a preparation method thereof, and a pyroptosis drug. Among them, the pyroptosis drug prodrug can target mitochondria, cause mitochondrial damage, release cytochrome c, activate Caspase3 to cleave GSDME, and cause cell pyroptosis. The drug prodrug (NCyNH2) is selective for tumor cells, reduces damage to normal cells, and can also detect its activation by the recovery of its own fluorescence. After intratumoral administration, the drug prodrug can effectively regulate the tumor immune microenvironment and activate T cell-mediated anti-tumor immune response. This molecule has great application prospects in mitochondrial targeting, inhibiting cell respiration, inducing cell pyroptosis, improving tumor immune microenvironment, and activating T cell-mediated anti-tumor immune response.

[0007] Although pyroptosis has shown great potential and importance in natural immune responses and tumor treatment, this field still faces some key challenges in practical applications. In particular, the types of reagents that can be used to induce pyroptosis are relatively limited, and the production costs of these reagents are generally high. This situation seriously restricts the widespread clinical application of pyroptosis-related therapies. In addition, the high cost of reagents has greatly limited the development speed of clinical and preclinical research in the field of pyroptosis. Therefore, the development of new and more cost-effective pyroptosis inducers to broaden the types of reagents and reduce treatment costs has become an urgent need for current research in this field. Summary of the invention

[0008] In response to the urgent need for cell pyroptosis inducers, the present invention provides the use of 1,3,5-tri(4-boronic acid phenyl)benzene as a cell pyroptosis inducer, and it is found that the compound has the effect of inducing cell pyroptosis and can be used to prepare therapeutic drugs for malignant tumors, autoimmune diseases, infectious diseases, neurodegenerative diseases, etc., and can induce pyroptosis of cancer cells or disease cells, thereby alleviating or treating related diseases, which has important promoting significance for clinical research.

[0009] To achieve the above object, the technical solution adopted by the present invention is:

[0010] The present invention finds that 1,3,5-tris(4-boronic acid phenyl)benzene has the effect of inducing cell pyroptosis and can be used in the preparation of cell pyroptosis inducers. The structure of 1,3,5-tris(4-boronic acid phenyl)benzene is as follows:

[0011]

[0012] Preferably, the cell pyroptosis inducer is used to prepare a drug for preventing or treating tumor diseases, autoimmune diseases, infectious diseases or neurodegenerative diseases.

[0013] Preferably, the cell pyroptosis inducer comprises 1,3,5-tris(4-boronic acid phenyl)benzene and other active ingredients.

[0014] Preferably, the other active ingredients include one or more of active ingredients that induce cell pyroptosis and are different from 1,3,5-tris(4-boronic acid phenyl)benzene, active ingredients that promote body functions, drugs that improve disease symptoms, and pharmaceutically acceptable excipients.

[0015] Preferably, the active pharmaceutical ingredient that induces cell pyroptosis and is different from 1,3,5-tris(4-boronic acid phenyl)benzene includes one or more of Paris saponin VI, α-ketoglutaric acid, triclabendazole, punica granatum tannin, and nigericin.

[0016] Preferably, the active ingredients that promote body functions include one or more of glucose, fermented cordyceps powder, wolfberry, ginseng, astragalus, ganoderma, polygonatum, atractylodes, codonopsis, salvia miltiorrhiza, angelica, and folic acid.

[0017] Preferably, the drug for improving disease symptoms includes one or more of immunotherapy drugs such as PD-L1 monoclonal antibody, chemotherapy drugs such as doxorubicin, and radiosensitizers such as paraoxonase. Preferably, the pharmaceutically acceptable excipients include one or more of dispersants, solubilizers, stabilizers, preservatives, sweeteners, flavoring agents, anti-caking agents, lubricants, disintegrants, and adsorbents.

[0018] Preferably, the tumor disease includes one or more of pancreatic cancer, lung cancer, liver cancer, colorectal cancer, breast cancer, gastric cancer, esophageal cancer, brain cancer, osteosarcoma, lymphoma, multiple myeloma, leukemia, and melanoma.

[0019] The present invention also provides the use of the cell pyroptosis inducer in constructing a cell pyroptosis model.

[0020] The present invention also provides a drug for preventing or treating tumor diseases, autoimmune diseases, infectious diseases or neurodegenerative diseases, wherein the main active ingredient of the drug is 1,3,5-tris(4-boronic acid phenyl)benzene.

[0021] The 1,3,5-tris(4-boronic acid phenyl)benzene has the effect of inducing cell pyroptosis.

[0022] The cells include human cancer cells or mammalian cells, such as canine, feline, horse, donkey, sheep, cow or pig cells.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] (1) The present invention is the first to discover that 1,3,5-tri(4-boronic acid phenyl)benzene has the effect of inducing cell pyroptosis. The compound has been industrially produced on a large scale at a low cost.

[0025] (2) The 1,3,5-tris(4-boronic acid phenyl)benzene in the present invention can be further synthesized into a multifunctional responsive pyroptosis inducer with stimulus response capability (such as reactive oxygen response, pH response) through its boronic acid group. This derivatization capability can overcome the side effects and biological toxicity of the pyroptosis inducers in the prior art. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 These are microscopic photographs of the pyroptosis behavior of pancreatic cancer cells induced by the drug-free group, 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene and 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene in Example 1.

[0027] Figure 2 This is a bar graph showing the release of LDH in pancreatic cancer cells induced by 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene at different drug concentrations in Example 2.

[0028] Figure 3 This is a bar graph comparing the effects of 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene and 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene on the proliferation of pancreatic cancer cells in Example 3.

[0029] Figure 4This is a heat map of the effect of 1,3,5-tri(4-boronic acid phenyl)benzene on genes related to the pyroptosis pathway of pancreatic cancer cells in Example 4. DETAILED DESCRIPTION

[0030] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiment. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. Those skilled in the art can make modifications or equivalent substitutions based on the understanding of the technical scheme of the present invention without departing from the spirit and scope of the technical scheme of the present invention, and all should be included in the protection scope of the present invention.

[0031] The raw materials used in the following specific embodiments are all purchased from the market.

[0032] Example 1

[0033] To verify that the pyroptotic activity of 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene is derived from the boronic acid group, 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene (CAS No.: 1017967-97-3) was selected as a control, and its structure is shown below:

[0034]

[0035] In this example, pancreatic cancer cells Bxpc-3 were selected for cell microscopic imaging experiments: when pancreatic cancer cells Bxpc-3 grew to 80% to 90% confluence, they were digested and centrifuged, dispersed in culture medium, and seeded into a 24-well cell culture plate at a density of 20,000 cells per well. After adhesion for 24 hours, 200 μL of fresh cell culture medium containing 20 μM 1,3,5-tris(4-boronic acid phenyl)benzene (P3B3), 20 μM 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene (P3B3-PIN) and no drugs were added respectively; after culturing for 1 day, cell microscopic photographs were taken.

[0036] The results are as follows Figure 1 As shown, (a) is a photo of pancreatic cancer cells in the drug-free group; (b) is a photo of pancreatic cancer cells incubated with 20μM 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene; (c) is a photo of pancreatic cancer cells incubated with 20μM 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene. It can be seen that at a low concentration of 20μM, 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene can effectively induce pyroptosis of pancreatic cancer cells. The cells in the figure show obvious cell swelling (indicated by the black arrow) and the proportion of swollen cells under the microscope exceeds 70%. However, the same concentration of 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene has no obvious effect on pancreatic cancer cells, and its cell morphology is basically the same as that of the control group.

[0037] Example 2

[0038] In order to study the ability of 1,3,5-tris(4-boronic acid phenyl)benzene to induce cells to release lactate dehydrogenase (LDH, a typical cell pyroptosis marker), pancreatic cancer cells Bxpc-3 were selected in this example for LDH release experiment: when pancreatic cancer cells Bxpc-3 grew to 80% to 90% confluence, they were digested and centrifuged, dispersed in culture medium, and seeded into 96-well cell culture plates at a density of 8000 cells per well. After adhesion for 24 hours, 200 μL of fresh cell culture medium containing 5 μM, 10 μM, and 20 μM 1,3,5-tris(4-boronic acid phenyl)benzene and 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene was added; after culturing for 24 hours, the cells were tested for LDH release.

[0039] Results Figure 2 , 1,3,5-tris(4-phenylboronic acid)benzene (P3B3) significantly induced LDH release, with an average LDH release of more than 40% at a dose of 20 μM, and showed a concentration-dependent manner. It can be expected that a higher concentration of 1,3,5-tris(4-phenylboronic acid)benzene can induce a greater amount of LDH release. However, the same dose of 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene (P3B3-PIN) did not lead to LDH release.

[0040] Example 3

[0041] In order to study the effect of 1,3,5-tris(4-boronic acid phenyl)benzene on the growth of pancreatic cancer cells, pancreatic cancer cells Bxpc-3 were selected in this example for cell proliferation behavior test experiment: when pancreatic cancer cells Bxpc-3 grew to 80% to 90% confluence, they were digested and centrifuged, dispersed in culture medium, and seeded into 96-well cell culture plates at a density of 5000 cells per well. After adhesion for 24 hours, 200 μL of fresh cell culture medium containing 5 μM, 10 μM, 20 μM 1,3,5-tris(4-boronic acid phenyl)benzene and 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene was added; after culturing for 24 hours, the cell density of the cells was counted.

[0042] The results are as follows Figure 3 As shown in the results, 1,3,5-tris(4-phenylboronic acid)benzene can effectively inhibit the proliferation of pancreatic cancer cells, especially when the dose reaches above 20 μM, the cell survival rate is about 20%. However, the same dose of 1,3,5-tris(4-phenylboronic acid pinacol ester)benzene has no obvious toxicity to cells, and the cell survival rate is greater than 90%.

[0043] Example 4

[0044] In order to explore the effect of 1,3,5-tris(4-boronic acid phenyl)benzene on genes related to the cell pyroptosis pathway, pancreatic cancer cell Bxpc-3 was selected for transcriptome sequencing (RNA-seq) in this example: when the pancreatic cancer cell Bxpc-3 grew to 80% to 90% confluence, it was digested and centrifuged, dispersed in the culture medium, and seeded into a 6-well cell culture plate at a density of 200,000 cells per well. After adhesion for 24 hours, 200 μL of fresh cell culture medium containing 5 μM, 10 μM, and 20 μM 1,3,5-tris(4-boronic acid phenyl)benzene was added; after culturing for 24 hours, the cells were collected for RNA-seq experiments.

[0045] The results are as follows Figure 4 As shown in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, P3B3 significantly affected the metabolic process of various amino acids in cells, and upregulated the gene expression of pyroptosis-related pathways such as PI3K-Akt and MAPK. This once again confirmed that P3B3 can significantly induce cell pyroptosis and then induce programmed cell death.

Claims

1. Application of 1,3,5-tri(4-boronic acid phenyl)benzene in the preparation of cell pyroptosis inducers.

2. The use according to claim 1, It is characterized in that The cell pyroptosis inducer is used to prepare a medicine for preventing or treating tumor diseases, autoimmune diseases, infectious diseases or neurodegenerative diseases.

3. The use according to claim 1, It is characterized in that The cell pyroptosis inducer comprises 1,3,5-tris(4-boronic acid phenyl)benzene and other active ingredients.

4. The use according to claim 1, It is characterized in that The other active ingredients include one or more of active ingredients that induce cell pyroptosis and are different from 1,3,5-tris(4-boronic acid phenyl)benzene, active ingredients that promote body functions, drugs that improve disease symptoms, and pharmaceutically acceptable excipients.

5. The use according to claim 1, It is characterized in that The active drug ingredient that induces cell pyroptosis and is different from 1,3,5-tris(4-boronic acid phenyl)benzene includes one or more of Paris saponin VI, α-ketoglutaric acid, triclabendazole, punica granatum tannin, and nigericin; The active ingredients that promote body functions include one or more of glucose, fermented cordyceps powder, wolfberry, ginseng, astragalus, ganoderma, polygonatum, atractylodes, codonopsis, salvia miltiorrhiza, angelica, and folic acid; The drug for improving disease symptoms includes one or more of immunotherapy drugs, chemotherapy drugs, and radiosensitizers; The pharmaceutically acceptable excipients include one or more of a dispersant, a solubilizer, a stabilizer, a preservative, a sweetener, a flavoring agent, an anti-caking agent, a lubricant, a disintegrant, and an adsorbent.

6. The use according to claim 1, It is characterized in that The tumor disease includes one or more of pancreatic cancer, lung cancer, liver cancer, colorectal cancer, breast cancer, gastric cancer, esophageal cancer, brain cancer, osteosarcoma, lymphoma, multiple myeloma, leukemia, and melanoma.

7. Use of the cell pyroptosis inducer according to claim 1 in constructing a cell pyroptosis model.

8. Use of the cell pyroptosis inducer according to claim 1 in the preparation of a medicament for preventing or treating tumor diseases, autoimmune diseases, infectious diseases or neurodegenerative diseases.

9. A drug for preventing or treating a tumor disease, an autoimmune disease, an infectious disease or a neurodegenerative disease, It is characterized in that The main active ingredient of the drug is 1,3,5-tris(4-boronic acid phenyl)benzene.

10. The drug according to claim 9, It is characterized in that The 1,3,5-tris(4-boronic acid phenyl)benzene has the effect of inducing cell pyroptosis.

Citation Information

Patent Citations

  • Pyroptosis drug prodrug, preparation method thereof and pyroptosis drug

    CN112939951A

  • Preparation and application of light-controlled pyroptosis inducer for targeting endoplasmic reticulum

    CN116730976A

  • New anti-tumor application of 3-boronic acid phenyl-1-aminoformic acid cholesterol ester and pharmaceutical preparation thereof

    CN112691111A